<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83768</article-id><article-id pub-id-type="doi">10.7554/eLife.83768</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-294223"><name><surname>Li</surname><given-names>Kexin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294224"><name><surname>Huo</surname><given-names>Qingji</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0438-6812</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294225"><name><surname>Dimmitt</surname><given-names>Nathan H</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-294226"><name><surname>Qu</surname><given-names>Guofan</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294227"><name><surname>Bao</surname><given-names>Junjie</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294228"><name><surname>Pandya</surname><given-names>Pankita H</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-294229"><name><surname>Saadatzadeh</surname><given-names>M Reza</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-294230"><name><surname>Bijangi-Vishehsaraei</surname><given-names>Khadijeh</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0009-2522-8806</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294231"><name><surname>Kacena</surname><given-names>Melissa A</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7293-0088</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-294232"><name><surname>Pollok</surname><given-names>Karen E</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-294233"><name><surname>Lin</surname><given-names>Chien-Chi</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4175-8796</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-294234"><name><surname>Li</surname><given-names>Bai-Yan</given-names></name><email>liby@ems.hrbmu.edu.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-273178"><name><surname>Yokota</surname><given-names>Hiroki</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7881-8959</contrib-id><email>hyokota@iupui.edu</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05jscf583</institution-id><institution>Department of Pharmacology, School of Pharmacy, Harbin Medical University</institution></institution-wrap><addr-line><named-content content-type="city">Harbin</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kg8sb98</institution-id><institution>Department of Biomedical Engineering, Indiana University Purdue University Indianapolis</institution></institution-wrap><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01f77gp95</institution-id><institution>Department of Orthopedic Surgery, Harbin Medical University Cancer Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Harbin</named-content></addr-line><country>China</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kg8sb98</institution-id><institution>Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052133d12</institution-id><institution>Department of Pediatrics, Indiana University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution>Department of Pediatric Hematology and Oncology, Indiana University School of Medicine</institution><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff><aff id="aff7"><label>7</label><institution>Department of Orthopaedic Surgery, Indiana University School of Medicine</institution><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01kg8sb98</institution-id><institution>Indiana Center for Musculoskeletal Health, Indiana University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Indianapolis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mohan</surname><given-names>Subburaman</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03z6z3n38</institution-id><institution>VA Loma Linda Healthcare System</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>21</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83768</elocation-id><history><date date-type="received" iso-8601-date="2022-09-28"><day>28</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-01"><day>01</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-10-21"><day>21</day><month>10</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.10.18.512687"/></event></pub-history><permissions><copyright-statement>© 2023, Li et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Li et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83768-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83768-figures-v1.pdf"/><abstract><p>Osteosarcoma (OS) is the common primary bone cancer that affects mostly children and young adults. To augment the standard-of-care chemotherapy, we examined the possibility of protein-based therapy using mesenchymal stem cells (MSCs)-derived proteomes and OS-elevated proteins. While a conditioned medium (CM), collected from MSCs, did not present tumor-suppressing ability, the activation of PKA converted MSCs into induced tumor-suppressing cells (iTSCs). In a mouse model, the direct and hydrogel-assisted administration of CM inhibited tumor-induced bone destruction, and its effect was additive with cisplatin. CM was enriched with proteins such as calreticulin, which acted as an extracellular tumor suppressor by interacting with CD47. Notably, the level of <italic>CALR</italic> transcripts was elevated in OS tissues, together with other tumor-suppressing proteins, including histone H4, and PCOLCE. PCOLCE acted as an extracellular tumor-suppressing protein by interacting with amyloid precursor protein, a prognostic OS marker with poor survival. The results supported the possibility of employing a paradoxical strategy of utilizing OS transcriptomes for the treatment of OS.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>osteosarcoma</kwd><kwd>MSC</kwd><kwd>proteome</kwd><kwd>calreticulin</kwd><kwd>CD47</kwd><kwd>PCOLCE</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>Biomechanics and Biomaterials Research Center at Indiana University Purdue University Indianapolis, USA</institution></institution-wrap></funding-source><award-id>NO. 2201-01</award-id><principal-award-recipient><name><surname>Yokota</surname><given-names>Hiroki</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009633</institution-id><institution>Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development</institution></institution-wrap></funding-source><award-id>NO. P50HD090215</award-id><principal-award-recipient><name><surname>Pollok</surname><given-names>Karen E</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>NCI Cancer Center Support Grant NO. P30CA082709</award-id><principal-award-recipient><name><surname>Pollok</surname><given-names>Karen E</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Tyler Trent Cancer Research Endowment for the Riley Hospital for Children IU-Health, USA</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Pollok</surname><given-names>Karen E</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006733</institution-id><institution>Indiana University</institution></institution-wrap></funding-source><award-id>Grand Challenge-Precision Health Initiative</award-id><principal-award-recipient><name><surname>Pollok</surname><given-names>Karen E</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The anti-tumor action of engineered mesenchymal stem cells highlights the double-edged role of oncoproteins in osteosarcoma, and suggests the possibility of developing a novel strategy for protein-based cancer therapy.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>A sarcoma is a malignant tumor arising from mesenchymal-originated connective tissues (<xref ref-type="bibr" rid="bib30">Vailas et al., 2019</xref>). Osteosarcoma (OS) is the most prevalent form of bone sarcoma, usually occurring in the lower limb of teenagers and young adults (<xref ref-type="bibr" rid="bib29">Taran et al., 2017</xref>). The primary therapeutic regimen is surgery combined with adjuvant chemotherapy. While the standard-of-care MAP therapy using a combination of methotrexate (MTX), Adriamycin (aka doxorubicin [DOX]), and cisplatin (CIS) has significantly improved the survival rate, the metastatic or recurrent OS remains difficult to treat (<xref ref-type="bibr" rid="bib38">Yu et al., 2019</xref>). To explore targeted therapies, prognostic markers in Wnt, PI3K, RANKL, and Notch pathways have been searched in OS pathobiology. However, few targetable mutations have been identified and the efficacy of immunotherapy is controversial (<xref ref-type="bibr" rid="bib35">Wu et al., 2020</xref>). Here, we examined the possible conversion of mesenchymal stem cells (MSCs) into induced tumor-suppressing cells (iTSCs). Paradoxically, the generation of iTSCs requires the activation of tumorigenic signaling. For instance, we have reported that the overexpression of β-catenin in canonical Wnt signaling and the activation of PI3K/Akt signaling can produce iTSCs and tumor-suppressive conditioned medium (CM) (<xref ref-type="bibr" rid="bib17">Liu et al., 2021a</xref>, <xref ref-type="bibr" rid="bib25">Sun et al., 2021</xref>). To develop a novel option for OS treatment, we examined the generation of MSC-driven iTSCs by activating protein kinase A (PKA) signaling.</p><p>T lymphocytes have been frequently employed for immunotherapy because of their immunomodulatory properties as well as their availability in the peripheral blood of patients (<xref ref-type="bibr" rid="bib31">Waldman et al., 2020</xref>). Here, we employed bone marrow-derived MSCs and occasionally adipose tissue-derived MSCs since MSCs are implantable stem cells that generate osteoblasts and osteocytes. In this study, the activation of three signaling pathways was evaluated, including Wnt, PI3K, and PKA pathways. PKA activation in MSCs was selected since it generated stronger anti-tumor effects than the activation of Wnt or PI3K. PKA is known as a cAMP-dependent protein kinase, which is triggered by cAMP (<xref ref-type="bibr" rid="bib32">Walsh and Van Patten, 1994</xref>). Using a mouse model of OS in the proximal tibia, we examined the efficacy of CM with and without the administration of CIS. CM was given as a daily intravenous injection or a weekly hydrogel-based administration (<xref ref-type="bibr" rid="bib16">Lin et al., 2022</xref>).</p><p>Previous iTSC studies have revealed that the activation of tumorigenic signaling elevates the levels of extracellular tumor-suppressing proteins, including calreticulin (CALR), enolase 1 (ENO1), heat shock protein 90ab1 (HSP), moesin (MSN), and ubiquitin C (UBC) (<xref ref-type="bibr" rid="bib25">Sun et al., 2021</xref>; <xref ref-type="bibr" rid="bib17">Liu et al., 2021a</xref>, <xref ref-type="bibr" rid="bib18">Liu et al., 2021b</xref>, <xref ref-type="bibr" rid="bib27">Sun et al., 2022b</xref>, <xref ref-type="bibr" rid="bib15">Li et al., 2022b</xref>). Importantly, the listed proteins are reported as tumorigenic in many types of cancers, and their pro-tumor actions inside the cells are reversed to the anti-tumor actions in the extracellular domain. To our surprise, the transcript levels of these tumor-suppressing proteins are significantly elevated in sarcoma tissues in the TCGA database. This observation led us to address an intriguing question as to whether the products of transcripts, which are highly expressed in OS tissues, may act as tumor-suppressing proteins in the extracellular domain.</p><p>As for the anti-tumor regulatory mechanism, we focused on CALR and procollagen C-endopeptidase enhancer (PCOLCE). CALR was enriched in iTSC CM as a chaperone protein in the endoplasmic reticulum, but it can be located in the cell surface and extracellular matrix (<xref ref-type="bibr" rid="bib10">Gold et al., 2010</xref>). PCOLCE, an enzyme that cleaves type I procollagen (<xref ref-type="bibr" rid="bib24">Steiglitz et al., 2006</xref>), was selected because of the elevated level of its transcripts in OS tissues. We have shown that CALR interacts with CD47 (<xref ref-type="bibr" rid="bib14">Li et al., 2022a</xref>), an integrin-associated transmembrane protein, which stimulates the escape of cancer cells from immune surveillance (<xref ref-type="bibr" rid="bib23">Sick et al., 2012</xref>). Interestingly, both CALR and PCOLCE are reported to interact with amyloid precursor protein (APP) in IntAct molecular interaction database (<xref ref-type="bibr" rid="bib21">Orchard et al., 2014</xref>). According to the TCGA database, the elevated level of APP transcripts of patients with sarcoma is a poor prognostic marker. Collectively, this study demonstrates a novel role of the CALR/PCOLCE-APP axis in OS progression and suggests APP as an OS-specific druggable target.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Suppression of the proliferation, migration, and invasion of OS cells by MSC CM</title><p>We first evaluated the efficacy of three pharmacological agents for inducing the tumor-suppressing capability of bone marrow-derived MSC-driven CM. Three agents were BML284, YS49, and CW008, which were known activators of Wnt, PI3K, and PKA signaling pathways, respectively. The MTT-based cell viability of three human OS cell lines (MG63, U2OS, TT2 PDX) was not altered by the control MSC CM without any agent treatments (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). However, BML284 (BML), YS49, and CW008 (CW) converted CM into the tumor-suppressing agent. Except for MG63 cells with BML284-treated MSC CM, all CM reduced MTT-based viability in three OS cell lines (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Among them, the strongest MTT inhibitory effect was obtained with CW008-treated MSC CM, which also decreased scratch-based motility and transwell invasion of TT2 PDX OS cells (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Suppression of the viability, migration, and invasion of osteosarcoma (OS) cells by CW008-treated mesenchymal stem cell (MSC) CM.</title><p>The double asterisk indicates p&lt;0.01. CN = control, CM = conditioned medium, BML = BML284 as a Wnt activator, YS49=PI3K activator, CW = CW008 as a PKA activator, MSC = bone marrow-derived MSC, and aMSC = adipose-derived MSC. (<bold>A</bold>) Reduction in MTT-based cell viability of three OS cell lines (MG63, U2OS, TT2 PDX) in 2 days by bone marrow-derived MSC CM, which were derived after the treatment with BML284, YS49, or CW008. (n=5). (B and C) Decrease in scratch-based motility (n=4) and transwell invasion (n=5) of TT2 OS cells in 2 days by CW008-treated MSC CM. (<bold>D–F</bold>) Inhibition of MT-based cell viability (n=6), scratch-based motility (n=4), and transwell invasion (n=5) of TT2 OS cells in 2 days by CW008-treated adipose-derived MSC. (Scale bar, 200 µm, error bars indicate standard deviation.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Effects of H89 (PKA inhibitor) and D-cAMP (cAMP analog as a PKA activator).</title><p>The single and double asterisks indicate p&lt;0.05 and 0.01, respectively. CN = control, and CM = conditioned medium. (A and B) Elevation of MTT-based cell viability (n=6) and transwell invasion (n=5) of TT2 osteosarcoma (OS) cells by H89-treated MSC-derived CM. (C and D) Reduction of MTT-based cell viability (n=6) and transwell invasion (n=5) of TT2 OS cells by D-cAMP-treated MSC-derived CM. (Scale bar, 200 µm, error bars indicate standard deviation.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig1-figsupp1-v1.tif"/></fig></fig-group><p>Besides bone marrow-derived MSCs, adipose-derived MSCs (aMSCs) were also used to generate tumor-suppressing CM by the treatment with CW008. CW008-treated aMSC CM inhibited the viability, migration, and invasion of TT2 OS cells (<xref ref-type="fig" rid="fig1">Figure 1D–F</xref>). The tumor-suppressing CM was also generated by cAMP analog, an activator of PKA signaling, while a PKA inhibitor, H89, oppositely generated tumor-promoting CM (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Collectively, the results revealed that the treatment of MSCs and aMSCs with CW008 generated anti-OS CM. Hereafter, this study focused on CW008-treated bone marrow-derived MSC CM (CW-MSC CM) and examined its anti-tumor role and regulatory mechanism using in vitro and in vivo models.</p></sec><sec id="s2-2"><title>Compatibility of CW-MSC CM with chemotherapeutic agents</title><p>The standard-of-care chemotherapy for OS employs a combination of MTX, DOX, and CIS. One of the major issues for the clinical application is the compatibility of CM with the existing chemotherapeutic agents. Importantly, the simultaneous application of CW-MSC CM significantly lowered the effective concentrations of MTX, DOX, and CIS in both TT2 and U2OS cells (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Western blot analysis revealed that CW-MSC CM induced the reduction of p-Src and Snail, as well as the elevation of cleaved caspase 3, a marker for apoptotic death, in TT2 OS cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Characterization of CW008-treated mesenchymal stem cell (MSC) CM.</title><p>The double asterisk indicated p&lt;0.01. CN = control, CW = CW008, CM = conditioned medium, Cas = caspase 3, exo = exosome, MTX = methotrexate, DOX = doxorubicin, and CIS = cisplatin. (A and B) Additive MTT-based anti-tumor effect of CW008-treated MSC CM with methotrexate, doxorubicin, and cisplatin in TT2 and U2OS cells, respectively. (<bold>C</bold>) Reduction of p-Src and Snail and elevation of cleaved caspase 3 in TT2 OS cells by CW008-treated MSC CM for 2 days. (D and E) No significant change of MTT-based viability by the nuclease treatment (n=5) and ultracentrifugation for exosome removal (n=6), respectively, of CW008-treated MSC CM. (<bold>F</bold>) Variable tumor-suppressing capability of the size-fractionated CW008-treated bone marrow-derived MSC CM (CW-MSC CM) portion. (n=5). The protein size in kD on the X-axis indicates the cutoff size. For instance, the bar for 100 kD indicates the MTT value for the fraction that includes proteins larger than 100 kD. (Error bars indicate standard deviation.)</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83768-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig2-v1.tif"/></fig><p>Prior to focusing on proteomes in CM in this study, the potential role of nucleic acids and exosomes in tumor-suppressive capability was evaluated. Accordingly, the anti-tumor action was not significantly altered either by DNA/RNA digestion with nucleases or exosome removal with ultracentrifugation (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>). Also, size-fractionated CM indicated that tumor-suppressing proteins were distributed in all fractions including proteins above and below 100 kD (<xref ref-type="fig" rid="fig2">Figure 2F</xref>). Of note, protein size in kD in the horizontal axis indicates the cutoff size, and the bar for 100 kD, for instance, corresponded to the fraction for proteins 100 kD and larger.</p></sec><sec id="s2-3"><title>Bone protection by CW-MSC CM with and without CIS</title><p>In the NSG mouse model of OS in the proximal tibia, the weekly intraperitoneal injection of CIS (10 µg/kg), the daily intravenous injection of CW-MSC CM, and their combination significantly reduced the degradation of trabecular bone by elevating the bone volume ratio (BV/TV) and bone mineral density (BMD) in 18 days after the inoculation of TT2 OS cells (2.5×10<sup>5</sup> cells) (N=6, <xref ref-type="fig" rid="fig3">Figure 3A</xref>; N=4, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Consistently, the cortical bone in the proximal tibia was also protected by the administration of CW-MSC CM with and without CIS, although the application of CIS alone at a dose of 10 µg/kg did not significantly restore BMD (N=6, <xref ref-type="fig" rid="fig3">Figure 3B</xref>). We also applied CW-MSC CM weekly using a hydrogel-based delivery system and observed that the weekly administration of hydrogel-embedded CM effectively protected trabecular and cortical bone for OS-induced degradation (N=5, <xref ref-type="fig" rid="fig3">Figure 3C and D</xref>; N=3, <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>). Notably, compared to the placebo group, immunohistochemical analysis showed that the administration of CW-MSC CM decreased Ki-67 and increased cleaved caspase 3 in tumor-invaded bone sections (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Protection of tumor-invaded bone by CW008-treated mesenchymal stem cell (MSC) CM.</title><p>pl = placebo, CIS = cisplatin, CW = CW008, CN = control, and CM = conditioned medium. The single and double asterisks indicate p&lt;0.05 and 0.01, respectively. (<bold>A</bold>) Additive prevention of bone loss in the tumor-invaded tibia by CW008-treated MSC CM with cisplatin (n=6). (<bold>B</bold>) Effect of CW008-treated MSC CM with cisplatin on tibial cortical bone (n=6). (C and D) Reduction in trabecular and cortical bone loss in the tumor-invaded proximal tibia by hydrogel CW008-treated MSC CM. BV/TV = bone volume ratio, BMD = bone mineral density (n=5). (Scale bar, 1 mm, error bars indicate standard deviation).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Histological analysis of tumor-invaded bone in response to CW008-treated MSC CM with and without cisplatin.</title><p>pl = placebo, CIS = cisplatin, CW = CW008, and CM = conditioned medium. The double asterisks indicate p&lt;0.01. (n=4, scale bar, 200 µm, error bars indicate standard deviation.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Histological analysis of reduction in trabecular bone loss in the tumor-invaded proximal tibia by hydrogel CW008-treated mesenchymal stem cell (MSC) CM.</title><p>CN = control, CW = CW008, and CM = conditioned medium. The single asterisk indicates p&lt;0.05. (n=3, scale bar, 200 µm, error bars indicate standard deviation.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Downregulation of Ki-67 and upregulation of cleaved caspase 3 in tumor-invaded bone sections by the administration of CW CM.</title><p>CW CM = CW008-treated MSC CM, and c-Cas = cleaved caspase 3. The single and double asterisks indicate p&lt;0.05 and 0.01, respectively. (n=3, scale bar, 50 µm, error bars indicate standard deviation.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig3-figsupp3-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>Tumor-suppressing proteins in CW-MSC CM</title><p>Previous studies for iTSCs showed that MSC CM, generated by the activation of Wnt and PI3K signaling pathways, were enriched with extracellular tumor-suppressing proteins such as CALR, ENO1, HSP, MSN, and UBC. Notably, western blot and ELISA revealed that the same tumor-suppressing proteins, enriched in other MSC CM, were also elevated in CW-MSC CM (<xref ref-type="fig" rid="fig4">Figure 4A–F</xref>). Furthermore, MMP2 and MMP9, which promote the migration and invasion of OS cells, were downregulated in CW-MSC CM (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Using an MTT assay, the anti-tumor efficacy of the selected five tumor-suppressing proteins were evaluated with TT2 OS cells. The value IC<sub>50</sub> for CW-MSC CM was 390 μg/ml (<xref ref-type="fig" rid="fig4">Figure 4G</xref>), while IC<sub>50</sub> for the selected tumor-suppressing proteins ranged from 1.1 μg/ml (CALR) to 5.8 μg/ml (HSP) (<xref ref-type="fig" rid="fig4">Figure 4H</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Tumor-suppressing proteins in CW008-treated mesenchymal stem cell (MSC) CM.</title><p>The single and double asterisks indicate p&lt;0.05 and 0.01, respectively. CM = conditioned medium, CW = CW008 (PKA activator), CALR = calreticulin, ENO1=enolase 1, HSP = heat shock protein 90ab1, MSN = moesin, UBC = ubiquitin C, MMP2 and MMP9=matrix metalloproteinases 2 and 9, Col I=type I collagen. (<bold>A</bold>) Western blot-based expression levels of CALR, ENO1, HSP, MSN, UBC, MMP2, MMP9, and Col I in CW008-treated MSC CM. (<bold>B–F</bold>) ELISA-based levels of five tumor-suppressing proteins (CALR, ENO1, HSP, MSN, and UBC) in CW008-treated MSC CM (n=3). (<bold>G</bold>) Dose responses of TT2 OS cells in response to CW008-treated MSC CM with IC<sub>50</sub> at 390 μg/ml (n=5). (<bold>H</bold>) Dose responses and IC<sub>50</sub> of TT2 OS cells in response to five tumor-suppressing proteins (CALR, ENO1, HSP, MSN, and UBC). (Error bars indicate standard deviation.)</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig4">Figure 4A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83768-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig4-v1.tif"/></fig></sec><sec id="s2-5"><title>CALR’s anti-tumor action on tumor-invaded bone</title><p>We have so far shown the tumor-suppressing capability of CW-MSC CM that contained the elevated level of the selected tumor-suppressing proteins. Since CALR was most significantly increased in CM (4.1×) and its IC<sub>50</sub> was the lowest among the five selected proteins, its OS-suppressing effect was tested in two groups of NSG mice, the placebo and CALR-treated groups. Mice (~8 weeks of age) received the inoculation of TT2 PDX cells in their proximal tibia by an intra-tibia injection, and CALR was administered at 10 μg/kg daily as a tail vein injection for 18 days. The placebo received a daily intravenous injection of the vehicle. X-ray images showed that compared to the placebo CALR-treated mice presented a smaller defect in the proximal tibia (<xref ref-type="fig" rid="fig5">Figure 5A</xref>), and the BMD of the cortical bone in the proximal tibia was higher (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Furthermore, microCT images of trabecular bone showed an increase in BV/TV and BMD in the proximal tibia (N=8, <xref ref-type="fig" rid="fig5">Figure 5C</xref>). Consistently, immunohistochemical analysis showed a decrease in Ki-67 and an increase in cleaved caspase 3 in tumor-invaded bone sections by the administration of CALR (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). Furthermore, the culturing of MC3T3 osteoblast cells in CW CM and CALR increased Alizarin Red staining in 3 weeks and elevated the levels of osteogenic genes such as type I collagen, alkaline phosphatase (ALP), and osteocalcin (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Calreticulin’s action on tumor-invaded bone and its interaction with CD47.</title><p>The single asterisk indicates p&lt;0.05. CALR = calreticulin, pl = placebo, siNC = nonspecific siRNA, siCD47=CD47 siRNA, CW CM = CW008-treated MSC conditioned medium, and Cas = caspase 3. (<bold>A</bold>) X-ray images of the proximal tibia of NSG mice that received inoculation of TT2 OS cells. (<bold>B</bold>) MicroCT image-based increase in BMD (bone mineral density) of cortical bone in the proximal tibia (N=8) of NSG mice by daily injection of calreticulin (10 μg/kg). (<bold>C</bold>) MicroCT image-based increase in BV/TV (bone volume ratio) and BMD of trabecular bone of NSG mice in the proximal tibia (n=8). (<bold>D</bold>) Reciprocal co-immunoprecipitation of calreticulin and CD47 using TT2 osteosarcoma (OS) cell lysate. (<bold>E</bold>) Suppression of calreticulin-induced changes of p-Src, Snail, and cleaved caspase 3 (c-Cas) in U2OS cells by silencing CD47. (<bold>F</bold>) Favorable %survival with a high level of calreticulin and a low level of CD47 in all cancer patients. (<bold>G</bold>) Elevated expression level of CD47 in three OS cell lines (U2OS, TT2, and MG63), compared to non-OS cells (MSCs). (<bold>H</bold>) Tumor selectivity, larger than 1 for CW008-treated MSC CM and calreticulin, indicating the selective inhibition of OS cells (TT2, U2OS, and MG63) compared to MSCs. Of note, tumor selectivity for cisplatin, smaller than 1, indicates cisplatin’s non-selective inhibition of tumor and non-tumor cells. (Scale bar, 1 mm, error bars indicate standard deviation.)</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig5">Figure 5D, E and G</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83768-fig5-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Downregulation of Ki-67 and upregulation of cleaved caspase 3 in tumor-invaded bone sections by the administration of calreticulin.</title><p>CALR = calreticulin, and c-Cas=cleaved caspase 3. The single and double asterisks indicate p&lt;0.05 and 0.01, respectively. (n=3, scale bar, 50 µm, error bars indicate standard deviation.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Stimulation of osteoblast differentiation by CW008-treated bone marrow-derived MSC CM (CW-MSC CM) and calreticulin.</title><p>CN = control, CW = CW008, CM = conditioned medium, CALR = calreticulin, COL I=type I collagen, and ALP = alkaline phosphatase. The double asterisks indicate p&lt;0.01. (<bold>A</bold>) Enhanced Alizarin Red staining of MC3T3 osteoblasts by the administration of CW-MSC CM and calreticulin. (<bold>B</bold>) Elevation of type I collagen, ALP, and osteocalcin by CW-MSC CM and calreticulin. The double asterisks indicate p&lt;0.01.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83768-fig5-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Silencing the CD47 in U2OS cells.</title><p>siNC = nonspecific control siRNA and siCD47=CD47 siRNA.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5—figure supplement 3—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83768-fig5-figsupp3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig5-figsupp3-v1.tif"/></fig><fig id="fig5s4" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 4.</label><caption><title>Suppression of CALR-driven decrease in MTT-based viability of U2OS osteosarcoma (OS) cells, TT2 OS cells, MDA-MB-231 breast cancer cells, and PANC1 pancreatic cells by partial silencing of CD47.</title><p>CALR = calreticulin, siNC = nonspecific control siRNA, and siCD47=CD47 siRNA. The single and double asterisks indicate p&lt;0.05 and 0.01, respectively. (n=4, error bars indicate standard deviation.)</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig5-figsupp4-v1.tif"/></fig><fig id="fig5s5" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 5.</label><caption><title>Elevation of the phosphorylation of eukaryotic translation initiation factor 2 alpha (p-eIF2a) in TT2 osteosarcoma (OS) cells by the application of calreticulin (CALR).</title><p><supplementary-material id="fig5s5sdata1"><label>Figure 5—figure supplement 5—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83768-fig5-figsupp5-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig5-figsupp5-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Involvement of the CALR-CD47 regulatory axis</title><p>CALR is reported as a pro-phagocytic protein with CD47, a transmembrane integrin-associated protein as its ligand, which prevents cancer cell phagocytosis (<xref ref-type="bibr" rid="bib5">Chao et al., 2010</xref>). Using a reciprocal pair of co-immunoprecipitations, we observed the interaction of CALR with CD47 using TT2 OS cell lysate (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). We also observed using RNA interference that CALR-induced downregulation of p-Src and Snail, as well as upregulation of caspase 3, was suppressed by silencing <italic>CD47</italic> in U2OS cells (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). Silencing <italic>CD47</italic> also downregulated MTT-based viability, whereas it significantly suppressed CALR-induced tumor inhibition in U2OS OS cells, TT2 OS cells, MDA-MB-231 breast cancer cells, and PANC1 pancreatic cells (<xref ref-type="fig" rid="fig5s4">Figure 5—figure supplement 4</xref>). In TCGA database, the overall survival of all cancer patients was favored with a high level of CALR and a low level of CD47 (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</p></sec><sec id="s2-7"><title>CALR’s tumor-selective action</title><p>Expression of CD47 was elevated in three OS cell lines (U2OS, TT2, and MG63), compared to MSCs (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Consistently, CW-MSC CM and CALR preferentially inhibited the MTT-based viability of three OS cell lines. Of note, tumor selectivity was defined as a ratio of MTT values between cancer cells and non-cancer cells. Its values larger than 1 indicate the selective inhibition of OS cells (TT2, U2OS, and MG63) compared to non-OS cells (MSCs). By contrast, tumor selectivity for CIS, which was smaller than 1, indicated CIS’s non-selective inhibition of tumor and non-tumor cells (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). <italic>CALR</italic> is also known as a chaperone in the endoplasmic reticulum. We observed that the application of CALR recombinant protein to TT2 OS cells elevated the phosphorylation level of eukaryotic translation initiation factor 2 alpha (eIF2α), which regulates the stress to the endoplasmic reticulum (<xref ref-type="fig" rid="fig5s5">Figure 5—figure supplement 5</xref>).</p></sec><sec id="s2-8"><title>Double-sword role of the selected genes that were upregulated in OS</title><p>In the TCGA database, five transcripts for the selected tumor-suppressing proteins (<italic>CALR, ENO1, HSP, MSN,</italic> and <italic>UBC</italic>) were significantly upregulated in OS cells (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). This observation raised an intriguing question as to whether highly expressed transcripts in OS cells could generate tumor-suppressing proteins. To test this counterintuitive hypothesis, we selected seven transcripts (<italic>SPARC, PCOLCE, CPE, GJA1, S100A11, HISTONE H4,</italic> and <italic>PPIB</italic>) that were highly expressed in OS cells (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). An MTT assay revealed that all proteins except for SPARC (5 µg/ml) showed tumor-suppressing capability (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). In CW-MSC CM, the levels of HISTONE H4, PPIB, and PCOLCE were elevated (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Because of the strongest effect of PCOLCE in the MTT assay, we focused on it and further analyzed its anti-tumor capability. The treatment with 1 μg/ml of PCOLCE reduced transwell invasion and scratch-based motility of TT2 OS cells (<xref ref-type="fig" rid="fig6">Figure 6D and E</xref>). Notably, a high level of PCOLCE significantly reduced the survival rate of all cancer patients (<xref ref-type="fig" rid="fig6">Figure 6F</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>TCGA database-based prediction of tumor suppressors and the effect of PCOLCE.</title><p>CN = control and APP = amyloid precursor protein. The single and double asterisks indicate p&lt;0.05 and 0.01, respectively. (<bold>A</bold>) List of five selected proteins that were expressed higher in sarcoma tissues than the normal tissues in the TCGA database. (<bold>B</bold>) Reduction in MTT-based proliferation of TT2 osteosarcoma (OS) cells by seven selected recombinant proteins (5 µg/ml) in 48 hr, which are selected with higher expression in sarcoma tissues in the TCGA database. (<bold>C</bold>) Western blot images, showing that the levels of H4, PPIB, and PCOLCE were elevated in CW008-treated bone marrow-derived MSC CM (CW-MSC CM). (D and E) Inhibition in the transwell invasion (48 hr) and scratch-based migration (24 hr) of TT2 OS cells by 1 µg/ml PCOLCE recombinant protein. (<bold>F</bold>) Lowered survival with a high level of PCOLCE in all cancer patients. (<bold>G</bold>) Protein candidates, which are connected with PCOLCE by IntAct network analysis. (<bold>H</bold>) Lowered survival rates of sarcoma patients with high levels of APP, while the opposite effect of all cancer types. (Scale bar, 200 µm, error bars indicate standard deviation.)</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig6">Figure 6C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83768-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig6-v1.tif"/></fig></sec><sec id="s2-9"><title>Anti-tumor regulatory action of the PCOLCE-APP axis</title><p>According to the IntAct protein interaction database, PCOLCE was shown to interact with APP, a cell-surface protein. Interestingly, APP also interacts with CALR (<xref ref-type="fig" rid="fig6">Figure 6G</xref>). Notably, a high level of APP transcripts significantly reduced the survival rate of sarcoma patients (p=0.0051). However, its high level was not a negative factor for the survival of patients with all cancer (<xref ref-type="fig" rid="fig6">Figure 6H</xref>).</p></sec><sec id="s2-10"><title>Interaction of APP with PCOLCE and CALR</title><p>To assess the potential mechanism of tumor-suppressive action of PCOLCE and CALR, we conducted an immunoprecipitation assay. The result revealed that the APP was co-immunoprecipitated with PCOLCE and CALR in TT2 cell lysates (<xref ref-type="fig" rid="fig7">Figure 7A</xref>). APP acted oncogenic, and its silencing in TT2 cells reduced the transwell invasion and scratch-based motility (<xref ref-type="fig" rid="fig7">Figure 7B–D</xref>). Silencing APP also downregulated MTT-based viability, whereas it significantly suppressed PCOLCE/CALR-induced tumor inhibition (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Furthermore, the silencing of APP in TT2 cells suppressed PCOLCE-mediated downregulation of p-Src and Snail, and upregulation of cleaved caspase 3 (<xref ref-type="fig" rid="fig7">Figure 7F</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Putative regulatory mechanism for the tumor-suppressing capability of CW008-treated mesenchymal stem cell (MSC) conditioned medium (CM).</title><p>CALR = calreticulin, siNC = nonspecific siRNA, siAPP = APP siRNA, and Cas = caspase 3. The single and double asterisks indicate p&lt;0.05 and 0.01, respectively. (<bold>A</bold>) Co-immunoprecipitation of amyloid precursor protein (APP) with PCOLCE and CALR. (<bold>B–D</bold>) Inhibition in the transwell invasion (48 hr) (n=5) and scratch-based migration (24 hr) (n=4) of TT2 osteosarcoma (OS) cells by silencing the APP. (<bold>E</bold>) Suppression of PCOLCE (n=4) and CALR (n=5)-driven decrease in MTT-based viability of TT2 OS cells by partial deletion of APP. (<bold>F</bold>) Suppression of PCOLCE-induced changes of p-Src and cleaved caspase 3 (c-Cas) in TT2 cells by silencing APP. (<bold>G</bold>) Schematic diagram for the regulatory mechanism of tumor-suppressing action of CW008-treated MSC CM. (Scale bar, 200 µm, error bars indicate standard deviation.)</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Original files for the gels in <xref ref-type="fig" rid="fig7">Figure 7A, B and F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-83768-fig7-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83768-fig7-v1.tif"/></fig></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>This study presented the generation of MSC-derived iTSCs by activating PKA signaling and evaluated the role of CALR-CD47 and PCOLCE-APP regulatory axes in suppressing the progression of OS (<xref ref-type="fig" rid="fig7">Figure 7G</xref>). In a traditional strategy, a gene with an elevated level of transcripts in cancer tissues is treated as a druggable target to be inhibited. In this study, we took a counterintuitive approach and showed the tumor-suppressive effects of their recombinant proteins. Together with the tumor-suppressing proteins such as CALR, ENO1, HSP, MSN, and UBC, which were enriched in tumor-suppressive CM, six recombinant proteins, such as HISTONE H4, PPIB, GJA1, CPE, S100A11, and PCOLCE, were identified as extracellular tumor-suppressing proteins. The results revealed a context-dependent role of proteins in CM and supported a paradoxical strategy to identify tumor-suppressing proteins. The study also demonstrated the hydrogel-based administration of CM to the site of tumor growth in the proximal tibia, and the compatibility of CM with CIS, a representative chemotherapeutic agent for OS treatment.</p><p>Among six tumor-suppressing proteins whose transcript levels were significantly elevated in OS tissues, two proteins (HISTONE H4 and PPIB) were enriched in iTSC CM in our previous studies (<xref ref-type="bibr" rid="bib17">Liu et al., 2021a</xref>, <xref ref-type="bibr" rid="bib25">Sun et al., 2021</xref>). HISTONE H4 is one of the five main histone proteins, and its extracellular form is cytotoxic via interactions with TLR2/4 (<xref ref-type="bibr" rid="bib19">Marsman et al., 2016</xref>). PPIB catalyzes the cis-trans isomerization of peptide bonds, but little is known about its tumor-suppressive mechanism. Three proteins (CPE, S100A11, and PCOLCE) are reported tumorigenic in OS and/or other cancer. CPE is an enzyme to catalyze the release of C-terminal arginine or lysine residues, and its N-terminal truncated form promotes the migration and invasion of OS cells via Wnt signaling (<xref ref-type="bibr" rid="bib7">Fan et al., 2019</xref>). S100A11 is reported to interact with miR-22 in MG63 OS cells, and it suppresses the anti-tumor action of miR-22 (<xref ref-type="bibr" rid="bib41">Zhou et al., 2018</xref>). PCOLCE binds to type I procollagen, and its upregulation is reported to promote metastasis in OS (<xref ref-type="bibr" rid="bib34">Wang et al., 2019</xref>). The role of GJA1, a member of the connexin family, is not well understood in OS progression. Collectively, the result clearly showed that tumorigenic transcripts, highly expressed in OS, frequently generate tumor-suppressing proteins in the extracellular domain.</p><p>The result revealed the significant role of the PCOLCE-APP regulatory axis in blocking OS progression. As a procollagen processing enzyme, PCOLCE is involved in the development of collagenous tissues, and its upregulation may induce an increase in collagen deposition and pathogenic fibrosis (<xref ref-type="bibr" rid="bib12">Kessler and Hassoun, 2019</xref>). It thus plays a role in the transformation of the tumor microenvironment. Its marked elevation in OS tissues is reported to promote lung metastasis (<xref ref-type="bibr" rid="bib34">Wang et al., 2019</xref>), and it is also upregulated in gastric cancer (<xref ref-type="bibr" rid="bib36">Xiang et al., 2020</xref>). APP is an integral membrane protein, expressed mostly in neuronal tissues. It is a precursor of amyloid beta that contributes to producing amyloid plaques found in the brains of Alzheimer’s disease patients. APP is also reported as one of the diagnostic biomarkers for OS (<xref ref-type="bibr" rid="bib39">Zhang and Yang, 2018</xref>), and its high expression reduces the survival of OS patients but not pan-cancer patients. Taken together, APP can be a druggable target, selective to OS, and PCOLCE is one of its biological blockers.</p><p>In the CALR-CD47 regulatory axis, the results in this study revealed that extracellular CALR inhibited CD47’s tumorigenic actions. CALR is a Ca<sup>2+</sup>-binding endoplasmic reticulum protein and is also detected on the cell surface as well as in extracellular space (<xref ref-type="bibr" rid="bib2">Arosa et al., 1999</xref>), and CD47 is an integrin-associated transmembrane protein. Although the role of CALR is reported context-dependent (<xref ref-type="bibr" rid="bib9">Fucikova et al., 2021</xref>), it in general oppositely mediates phagocytosis. A pro-phagocytic signal of CALR is counteracted by CD47 (<xref ref-type="bibr" rid="bib5">Chao et al., 2010</xref>), and blockage of CD47 is reported to induce in vivo tumor elimination by stimulating phagocytosis of cancer cells (<xref ref-type="bibr" rid="bib5">Chao et al., 2010</xref>). Consistently, the inhibition of CD47 is reported to block the progression of OS in a mouse model (<xref ref-type="bibr" rid="bib37">Xu et al., 2015</xref>). In this study, the level of CALR was upregulated 4.1-fold in CW-MSC CM, and the level of CD47 was higher in three OS cell lines than MSCs and osteocytes.</p><p>Translationally, the application of CM for any cancer treatment is far from mainstream compared to chemotherapeutic drugs. Its potential advantage is its integrity as a therapeutic agent with thousands of protein species. Alternatively, the selection of potent tumor-suppressing proteins such as CALR, ENO1, PCOLCE, etc. can be another option to construct a protein cocktail. The cocktail proteins can be developed based on the transcriptome of OS tissues of individual patients. The advantage of the use of MSCs is their immune privilege, and allogenic MSCs may not elicit inflammatory responses, mainly due to their lack of class-II major histocompatibility complex (<xref ref-type="bibr" rid="bib1">Ankrum et al., 2014</xref>). We mainly used bone marrow-derived MSCs in this study, but adipose tissue-derived MSCs were also able to generate iTSCs and tumor-suppressive CM.</p><p>In this study, we presented the marked anti-OS action of PKA-activated MSC CM and CALR, as well as CM’s compatibility with CIS in a mouse model of OS. Although MSC CM contains other biomolecules such as nucleic acids, small metabolites, lipids, etc., we focused herein on proteomes since the treatment with nucleases, a removal of exosomes by ultracentrifugation, and filtering with 3 kD cutoff did not significantly alter CM’s anti-tumor action. Also, we mainly employed CW008 and activated PKA signaling, but CW008 is known to promote osteogenic differentiation of MSCs (<xref ref-type="bibr" rid="bib13">Kim et al., 2013</xref>) which may indirectly affect the composition of MSC CM. Lastly, the most frequent site of OS-associated metastasis is the lung. We have previously shown that the administration of PI3K-activated MSC-derived CM suppressed breast cancer-associated lung metastasis using a mouse model (<xref ref-type="bibr" rid="bib26">Sun et al., 2022a</xref>). Besides the inhibition of the primary bone tumor, it is recommended to evaluate CM’s inhibitory action for the metastasized tumor in the lung.</p><p>The study disclosed an uncommon use of OS-elevated transcripts as a candidate for producing OS-inhibiting proteins. In addition to tumor-suppressing proteins that were enriched in CW-MSC CM such as CALR, we identified PCOLCE as a novel tumor-suppressing protein and proposed a regulatory axis of PCOLCE-APP for the treatment of OS. In summary, we demonstrated that bone marrow-derived MSCs can be converted into iTSCs and their proteomes can be used to protect the bone, in a combinatorial application with CIS. The therapeutic CM was also given locally to the tibia using a PADO hydrogel-based delivery system. The PADO hydrogels were injectable, cured in situ, and degraded within 1 week in vivo (<xref ref-type="bibr" rid="bib16">Lin et al., 2022</xref>). We envision that the described approach can be used to identify cell-surface receptors as druggable targets that mediate CM’s anti-tumor action.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture and agents</title><p>MG63 and U2OS human OS cell lines (#86051601-1VL and #92022711-1VL, Sigma, St Louis, MO, USA), and a patient-derived xenograft (PDX) TT2-77 xenoline were grown in DMEM (<xref ref-type="bibr" rid="bib22">Pandya et al., 2020</xref>). Human MSCs (#PT-2501, Lonza, Basel, Switzerland) and human aMSCs (#SCC038, Sigma) were grown in MSCBM (#PT-3238, Lonza). MDA-MB-231 breast cancer cells (ATCC, Manassas, VA, USA) were grown in αMEM. MC3T3 osteoblasts (Sigma, St Louis, MO, USA), and PANC1 (ATCC) were grown in DMEM. The culture media were supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 units/ml penicillin, and 100 µg/ml streptomycin; #15140122, Life Technologies, Grand Island, NY, USA), and cells were maintained at 37°C and 5% CO<sub>2</sub>. The identity of MG63, U2OS, MDA-MB-231, MC3T3, and PANC1 cell lines was authenticated by DNA fingerprinting using a cell line authentication kit (ATCC), and TT2-77 xenoline was authenticated by IDEXX BioAnalytics. All these cell lines tested negative for mycoplasma contamination.</p><p>The recombinant proteins, including CALR (MBS2009125), ENO1 (MBS2009113), MSN (MBS2031729), UBC (MBS2029484, MyBioSource, San Diego, CA, USA), and HSP(OPCA05157, Aviva Systems Biology, San Diego, CA, USA) were given to TT2 cells, and cells were incubated for 48 hr. The activators for Wnt signaling (BML284, 0.2 µM, SC-222416, Santa Cruz, Dallas, TX, USA) (<xref ref-type="bibr" rid="bib33">Wang et al., 2009</xref>), PI3K/Akt (YS-49, 50 µM, HY-15477, MCE, NJ, USA) (<xref ref-type="bibr" rid="bib11">Hsu et al., 2014</xref>), and PKA signaling (CW008, 20 µM, #5495, Tocris, Minneapolis, MN, USA) (<xref ref-type="bibr" rid="bib13">Kim et al., 2013</xref>) were applied to cells for 24 hr.</p></sec><sec id="s4-2"><title>Preparation of CM</title><p>For in vitro experiments, CM was subjected to low-speed centrifugation at 2000 rpm for 10 min. The cell-free supernatants were centrifuged at 4000 rpm for 10 min and subjected to filtration with a 0.22 μm polyethersulfone membrane (#SLGPR33RS, Sigma, St Louis, MO, USA). The supernatants were further centrifuged at 10,000×<italic>g</italic> for 30 min at 4°C to remove remaining cell debris and at 100,000×<italic>g</italic> (Type 90 Ti Rotor, Beckman, Brea, CA, USA) overnight at 4°C to remove exosomes. For examining the efficacy of CM in vivo, FBS-free CM was condensed by a filter with a cutoff molecular weight of 3 kD, and the condensed CM (50 µl resuspended in PBS) was intravenously injected from the tail vein. To evaluate the effect of nucleic acids on the anti-tumor action of CM, we treated CM with nucleases for digesting DNA and RNA (#PI88700, Thermo Fisher Scientific, Waltham, MA, USA). We also used four filters with different cutoff weights of 3, 10, 30, and 100 kD (#UFC900324, #UFC8010, #UFC8030, #UFC8100, Sigma) and evaluated the anti-tumor efficacy of the size-fractionated CMs.</p></sec><sec id="s4-3"><title>MTT assay</title><p>MTT-based metabolic activity was evaluated using ~2000 cells seeded in 96-well plates (#CLS3585, Corning, Glendale, AZ, USA). CM or recombinant proteins was given on day 2, and cells were dyed with 0.5 mg/ml thiazolyl blue tetrazolium bromide (#M5655-1G, Sigma) on day 4 for 4 hr. Optical density for assessing metabolic activities was determined at 562 nm using a multi-well spectrophotometer.</p></sec><sec id="s4-4"><title>Transwell invasion assay</title><p>The invasion capacity of OS cells was determined using a 12-well plate and transwell chambers (#353182, Thermo Fisher Scientific) with 8 µm pore size. Transwell chambers were coated with 300 µl Matrigel (#354234, Thermo Fisher Scientific, 100 µg/ml) that was polymerized and dried overnight. Five hundred µl of the serum-free medium was added to each chamber and after 1 hr, the chamber was washed three times with the serum-free medium. Approximately 7×10<sup>4</sup> cells in 300 µl serum-free DMEM were then placed in the upper chamber and 800 µl CM was added to the lower chamber. After 48 hr, the cells on the upper surface of the membrane were removed. The cells, which invaded the lower side of the membrane, were fixed and stained with 100% methanol and Crystal Violet (diluted 1:25 in water) for 30 min. At least five randomly chosen images were taken with an inverted optical microscope (magnification, ×100, Nikon, Tokyo, Japan), and the average number of stained cells, which represented the invasion capacity, was determined.</p></sec><sec id="s4-5"><title>Two-dimensional motility scratch assay</title><p>A motility scratch assay was conducted to evaluate two-dimensional migratory behavior. Approximately 4×10<sup>5</sup> cells were seeded in 12-well plates. After cell attachment, a plastic pipette tip was used to scratch a gap on the cell layer. The floating cells were removed, and CM or recombinant protein was added. Images of the cell-free scratch zone were taken at 0 hr, and the areas newly occupied with cells were determined 24 hr after the scratching. The areas were quantified with Image J (National Institutes of Health, Bethesda, MD, USA).</p></sec><sec id="s4-6"><title>Western blot analysis and ELISA</title><p>Cultured cells were lysed in a radio-immunoprecipitation assay buffer. Proteins were fractionated by 10–15% SDS gels and electro-transferred to polyvinylidene difluoride transfer membranes (#IPVH00010, Millipore, Billerica, MA, USA). The membrane was incubated overnight with primary antibodies and then with secondary antibodies conjugated with horseradish peroxidase (#7074S and #7076S, Cell Signaling, Danvers, MA, USA). Antibodies against p-Src (#2105S), Src (#2108S), p-eIF2α (#9721S), eIF2α (#9722S), Snail (#3879S), cleaved caspase 3 (#9661S), caspase 3 (#9662S), CALR (#2891S), ENO1 (#3810S), MSN (#3146S), APP (#2452S), MMP2 (#87809S) (Cell Signaling), MMP9 (#sc-393859), PCOLCE (#sc-73002), ALP (#sc-28904) (Santa Cruz, Dallas, TX, USA), HSP, osteocalcin (#ab203085, #ab93876, Abcam, Boston, MA, USA), CD47 (#MA5-11895), UBC (#PA5-76144) (Thermo Fisher Scientific), and type I collagen (#NB600-408, Novus Biologicals, CO, USA) were employed with β-actin as a control (#A5441, Sigma). The level of proteins was determined using a SuperSignal west femto maximum sensitivity substrate (#34096, Thermo Fisher Scientific), and a luminescent image analyzer (LAS-3000, Fuji Film, Tokyo, Japan) was used to quantify signal intensities. The levels of CALR, ENO1, HSP, MSN, and UBC in CW008-treated CM were determined using the ELISA kits (MBS263181, MBS1604563, MBS7700502, MBS2709503, and MBS267048; MyBioSource).</p></sec><sec id="s4-7"><title>RNA interference</title><p>RNA interference was conducted using siRNA specific to <italic>CD47</italic> and <italic>APP</italic> (#s1501, #145977; Thermo Fisher Scientific) with a negative siRNA (Silencer Select #1, Thermo Fisher Scientific) as a nonspecific control using the procedure previously described (<xref ref-type="bibr" rid="bib20">Minami et al., 2017</xref>).</p></sec><sec id="s4-8"><title>Immunoprecipitation</title><p>Immunoprecipitation was conducted with an immunoprecipitation starter pack kit (#45-000-369, Cytiva, Marlborough, MA, USA), using the procedure the manufacturer provided. In brief, 20 µl of protein A sepharose was washed twice with PBS and incubated with 2 µg of antibodies for CALR, CD47, or PCOLCE. In parallel, control IgG was prepared for negative control. The antibody crosslinked beads were incubated overnight with 600 µl TT2 cell protein samples on a shaker. The beads were collected by centrifugation, washed three times with PBS, and resuspended for western blotting. The protein samples before the immunoprecipitation were used as positive controls. Western blotting was conducted using antibodies against CALR, CD47, PCOLCE, and APP.</p></sec><sec id="s4-9"><title>Differentiation of osteoblasts</title><p>To evaluate the effect of CW-MSC CM and CALR recombinant protein on the differentiation of osteoblasts, MC3T3 osteoblasts were cultured in the osteogenic medium that consisted of 50 µg/ml ascorbic acid and 10 mM sodium β-glycerophosphate with 10% FBS and antibiotics. The medium was exchanged every 3 days, and cells were fixed and stained with Alizarin Red to visualize calcium deposits in 3 weeks.</p></sec><sec id="s4-10"><title>Immunohistochemistry</title><p>Using immunohistochemical staining, we detected the expression levels of Ki-67 (#ab16667, Abcam) and cleaved caspase 3 in the sagittal sections of the proximal tibia approximately 2 mm distal to the growth plate. After deparaffinization, the sections were placed in a 10 mM citric acid buffer for antigen activation. The sections were incubated with primary antibodies, followed by an ALP-conjugated secondary antibody, which was used for chromogenic staining. The sections were counterstained with hematoxylin. The immunostained area was quantified in the tumor-invaded area.</p></sec><sec id="s4-11"><title>Prediction of tumor-suppressing proteins from TCGA database</title><p>Seven tumor-suppressing protein candidates, including SPARC, histone H4, PPIB, GJA1, CPE, S100A11, and PCOLCE, were predicted from the transcriptomes in the TGCA database. The transcript levels of these candidates were elevated at least two times in OS tissues. We previously showed that extracellular histone H4 and PPIB acted as tumor-suppressing proteins in breast cancer (<xref ref-type="bibr" rid="bib17">Liu et al., 2021a</xref>, <xref ref-type="bibr" rid="bib25">Sun et al., 2021</xref>), while the five others were reported to stimulate the progression of OS when present in the intracellular domain (<xref ref-type="bibr" rid="bib6">Chen et al., 2021</xref>; <xref ref-type="bibr" rid="bib34">Wang et al., 2019</xref>; <xref ref-type="bibr" rid="bib40">Zhang et al., 2021</xref>; <xref ref-type="bibr" rid="bib28">Talbot et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Zhou et al., 2018</xref>). To examine anti-tumor capabilities, we employed the recombinant proteins (MBS553651, MBS2097677, MBS2009092, MBS2029317, MBS146520, MBS2557159, MBS2031097; MyBioSource), respectively. In the MTT assay, 5 μg/ml of each of these recombinant proteins was added to the medium and the alteration in the metabolic activity of OS cells was evaluated in 2 days.</p></sec><sec id="s4-12"><title>Animal models</title><p>The experimental procedures were approved by the Indiana University Animal Care and Use Committee and complied with the Guiding Principles in the Care and Use of Animals endorsed by the American Physiological Society. Mice were randomly housed five per cage by a stratified randomization procedure based on body weight. Mouse chow and water were provided ad libitum. In the mouse model of osteolysis, NOD/SCID/γ (-/-) (NSG) female mice (~8 weeks) were provided by the In Vivo Therapeutics Core of the Indiana University Simon Comprehensive Cancer Center (Indianapolis, IN, USA). Mice were divided into four groups (placebo, CIS, CW CM, and CW CM and CIS groups; six mice per group) in the first experiment, while they were divided into two groups (hydrogel CN CM and hydrogel CW CM groups; five mice per group) in the second experiment. They received an injection of TT2 cells (2.5×10<sup>5</sup> cells in 20 µl PBS), into the right tibia as an intra-tibial injection. From day 2, mice in the CM treatment groups received a daily intravenous injection of 50 µl CW-treated MSC CM, while CIS treatment groups received a weekly intraperitoneal injection of 10 μg/kg. The hydrogel groups received a weekly subcutaneous injection of 50 µl PADO hydrogel with lyophilized CM powder. For examining the efficacy of CALR, NSG female mice were divided into two groups (placebo and CALR groups; eight mice per group) and received an intra-tibial injection of TT2 cells (2.5×10<sup>5</sup> cells in 20 µl PBS) to the right tibia on day 1. From day 2, mice were given a daily intravenous injection of PBS (placebo group) or 10 μg/kg of CALR recombinant protein (CALR group). The animals were sacrificed on day 18, and the hindlimbs were harvested for microCT imaging and histology.</p></sec><sec id="s4-13"><title>Injectable hydrogel fabrication</title><p>Poly (diacetone acrylamide-co-di (ethylene glycol) ethyl ether acrylate-co-oligo (ethylene glycol) methyl ether acrylate), or PADO, was synthesized using reversible addition-fragmentation chain-transfer (RAFT) polymerization as previously reported (<xref ref-type="bibr" rid="bib16">Lin et al., 2022</xref>). The monomers feed ratios were 29, 59, and 13 mol% for diacetone acrylamide, di (ethylene glycol) ethyl ether acrylate, and oligo (ethylene glycol) methyl ether acrylate, respectively. PADO was crosslinked via acyl hydrazone chemistry using adipic dihydrazide (ADH) as the crosslinker. In addition to the acyl hydrazone crosslink, PADO was physically crosslinked due to phase separation occurring above room temperature. For conditioned media encapsulation, 15 wt% PADO was first reacted with ADH with hydrazide to ketone ratio of one overnight. Lyophilized conditioned media powder was reconstituted using low glucose DMEM and added to the polymer solution. Prior to injection, PADO hydrogel precursor solution was sterilized using germicidal UV light and then 50 μl was injected into each leg.</p></sec><sec id="s4-14"><title>X-ray</title><p>Whole-body X-ray imaging was performed using a Faxitron radiographic system (Faxitron X-ray Co., Tucson, AZ, USA) (<xref ref-type="bibr" rid="bib3">Bonar et al., 2012</xref>). Tibial integrity was scored in a blinded manner on a scale of 0–3: 0 = normal with no indication of a tumor, 1 = clear bone boundary with slight periosteal proliferation, 2 = bone damage and moderate periosteal proliferation, and 3 = severe bone erosion.</p></sec><sec id="s4-15"><title>μCT imaging and histology</title><p>The tibiae were harvested for μCT imaging and histology. Micro-computed tomography was performed using Skyscan 1172 (Bruker-MicroCT, Kontich, Belgium) (<xref ref-type="bibr" rid="bib4">Bouxsein et al., 2010</xref>). Using manufacturer-provided software, scans were performed at pixel size 8.99 μm and the images were reconstructed (nRecon v1.6.9.18) and analyzed (CTan v1.13). Using µCT images, trabecular bone parameters such as BV/TV and BMD were determined in a blinded fashion, as well as cortical bone parameters such as BMD. In histology, H&amp;E staining was conducted as described previously and images were analyzed in a blinded fashion (<xref ref-type="bibr" rid="bib8">Fan et al., 2020</xref>). Of note, normal bone cells appeared in a regular shape with round and deeply stained nuclei, while tumor cells were in a distorted shape with irregularly stained nuclei.</p></sec><sec id="s4-16"><title>Statistical analysis</title><p>For cell-based experiments, three or four independent experiments were conducted, and data were expressed as mean ± SD. In animal experiments, we employed at least five mice per group to obtain statistically significant differences in BV/TV and BMD for trabecular bone and BMD for cortical bone as a primary outcome measure. Statistical significance was evaluated using a one-way analysis of variance (ANOVA). Post hoc statistical comparisons with control groups were performed using Bonferroni correction with statistical significance at p&lt;0.05. The single and double asterisks in the figures indicate p&lt;0.05 and p&lt;0.01, respectively.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Supervision, Funding acquisition, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Supervision, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal experiments were conducted according to protocols approved by the Indiana University Animal Care and Use Committee and complied with the Guiding Principles in the Care and Use of Animals endorsed by the American Physiological Society (protocol #345R).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of seven selected proteins that were expressed higher in sarcoma tissues than the normal tissues in the TCGA dataset.</title></caption><media xlink:href="elife-83768-supp1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83768-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Data available at Dryad: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.m905qfv4w">https://doi.org/10.5061/dryad.m905qfv4w</ext-link>.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Huo</surname><given-names>Q</given-names></name><name><surname>Dimmitt</surname><given-names>NH</given-names></name><name><surname>Qu</surname><given-names>G</given-names></name><name><surname>Bao</surname><given-names>J</given-names></name><name><surname>Pandya</surname><given-names>PH</given-names></name><name><surname>Saadatzadeh</surname><given-names>MR</given-names></name><name><surname>Bijangi-Vishehsaraei</surname><given-names>K</given-names></name><name><surname>Kacena</surname><given-names>MA</given-names></name><name><surname>Pollok</surname><given-names>KE</given-names></name><name><surname>Lin</surname><given-names>C-C</given-names></name><name><surname>B-Y</surname><given-names>Li</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><source>Dryad Digital Repository</source><pub-id pub-id-type="doi">10.5061/dryad.m905qfv4w</pub-id><year iso-8601-date="2023">2023</year><data-title>Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins</data-title></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors appreciated the Indiana Pediatrics Biobank for the collection and processing of TT2 OS tissues and cells.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ankrum</surname><given-names>JA</given-names></name><name><surname>Ong</surname><given-names>JF</given-names></name><name><surname>Karp</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mesenchymal stem cells: immune evasive, not immune privileged</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/nbt.2816</pub-id><pub-id pub-id-type="pmid">24561556</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arosa</surname><given-names>FA</given-names></name><name><surname>de Jesus</surname><given-names>O</given-names></name><name><surname>Porto</surname><given-names>G</given-names></name><name><surname>Carmo</surname><given-names>AM</given-names></name><name><surname>de Sousa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules</article-title><source>The Journal of Biological Chemistry</source><volume>274</volume><fpage>16917</fpage><lpage>16922</lpage><pub-id pub-id-type="doi">10.1074/jbc.274.24.16917</pub-id><pub-id pub-id-type="pmid">10358038</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonar</surname><given-names>SL</given-names></name><name><surname>Brydges</surname><given-names>SD</given-names></name><name><surname>Mueller</surname><given-names>JL</given-names></name><name><surname>McGeough</surname><given-names>MD</given-names></name><name><surname>Pena</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Grimston</surname><given-names>SK</given-names></name><name><surname>Hickman-Brecks</surname><given-names>CL</given-names></name><name><surname>Ravindran</surname><given-names>S</given-names></name><name><surname>McAlinden</surname><given-names>A</given-names></name><name><surname>Novack</surname><given-names>DV</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Civitelli</surname><given-names>R</given-names></name><name><surname>Hoffman</surname><given-names>HM</given-names></name><name><surname>Mbalaviele</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e35979</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035979</pub-id><pub-id pub-id-type="pmid">22558291</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouxsein</surname><given-names>ML</given-names></name><name><surname>Boyd</surname><given-names>SK</given-names></name><name><surname>Christiansen</surname><given-names>BA</given-names></name><name><surname>Guldberg</surname><given-names>RE</given-names></name><name><surname>Jepsen</surname><given-names>KJ</given-names></name><name><surname>Müller</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Guidelines for assessment of bone microstructure in rodents using micro-computed tomography</article-title><source>Journal of Bone and Mineral Research</source><volume>25</volume><fpage>1468</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1002/jbmr.141</pub-id><pub-id pub-id-type="pmid">20533309</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chao</surname><given-names>MP</given-names></name><name><surname>Jaiswal</surname><given-names>S</given-names></name><name><surname>Weissman-Tsukamoto</surname><given-names>R</given-names></name><name><surname>Alizadeh</surname><given-names>AA</given-names></name><name><surname>Gentles</surname><given-names>AJ</given-names></name><name><surname>Volkmer</surname><given-names>J</given-names></name><name><surname>Weiskopf</surname><given-names>K</given-names></name><name><surname>Willingham</surname><given-names>SB</given-names></name><name><surname>Raveh</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Majeti</surname><given-names>R</given-names></name><name><surname>Weissman</surname><given-names>IL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47</article-title><source>Science Translational Medicine</source><volume>2</volume><elocation-id>63ra94</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3001375</pub-id><pub-id pub-id-type="pmid">21178137</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>S-J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Liao</surname><given-names>Q-M</given-names></name><name><surname>Zou</surname><given-names>Y-S</given-names></name><name><surname>Pei</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CCAR2 promotes a malignant phenotype of osteosarcoma through wnt/β-catenin-dependent transcriptional activation of SPARC</article-title><source>Biochemical and Biophysical Research Communications</source><volume>580</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2021.09.070</pub-id><pub-id pub-id-type="pmid">34624572</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Carboxypeptidase E-δN promotes migration, invasiveness, and epithelial-mesenchymal transition of human osteosarcoma cells via the Wnt-β-catenin pathway</article-title><source>Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire</source><volume>97</volume><fpage>446</fpage><lpage>453</lpage><pub-id pub-id-type="doi">10.1139/bcb-2018-0236</pub-id><pub-id pub-id-type="pmid">30508384</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Jalali</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Teli</surname><given-names>M</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Na</surname><given-names>S</given-names></name><name><surname>Agarwal</surname><given-names>M</given-names></name><name><surname>Robling</surname><given-names>AG</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Skeletal loading regulates breast cancer-associated osteolysis in a loading intensity-dependent fashion</article-title><source>Bone Research</source><volume>8</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1038/s41413-020-0083-6</pub-id><pub-id pub-id-type="pmid">32128277</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fucikova</surname><given-names>J</given-names></name><name><surname>Spisek</surname><given-names>R</given-names></name><name><surname>Kroemer</surname><given-names>G</given-names></name><name><surname>Galluzzi</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Calreticulin and cancer</article-title><source>Cell Research</source><volume>31</volume><fpage>5</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0383-9</pub-id><pub-id pub-id-type="pmid">32733014</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gold</surname><given-names>LI</given-names></name><name><surname>Eggleton</surname><given-names>P</given-names></name><name><surname>Sweetwyne</surname><given-names>MT</given-names></name><name><surname>Van Duyn</surname><given-names>LB</given-names></name><name><surname>Greives</surname><given-names>MR</given-names></name><name><surname>Naylor</surname><given-names>S-M</given-names></name><name><surname>Michalak</surname><given-names>M</given-names></name><name><surname>Murphy-Ullrich</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Calreticulin: non-endoplasmic reticulum functions in physiology and disease</article-title><source>FASEB Journal</source><volume>24</volume><fpage>665</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1096/fj.09-145482</pub-id><pub-id pub-id-type="pmid">19940256</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>Y-H</given-names></name><name><surname>Chang</surname><given-names>C-C</given-names></name><name><surname>Yang</surname><given-names>N-J</given-names></name><name><surname>Lee</surname><given-names>Y-H</given-names></name><name><surname>Juan</surname><given-names>S-H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Rhoa-Mediated inhibition of vascular endothelial cell mobility: positive feedback through reduced cytosolic p21 and p27</article-title><source>Journal of Cellular Physiology</source><volume>229</volume><fpage>1455</fpage><lpage>1465</lpage><pub-id pub-id-type="doi">10.1002/jcp.24583</pub-id><pub-id pub-id-type="pmid">24535918</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>E</given-names></name><name><surname>Hassoun</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Procollagen C-proteinase enhancer 1 (PCPE-1) in liver fibrosis</article-title><source>Methods in Molecular Biology</source><volume>1944</volume><fpage>189</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-9095-5_14</pub-id><pub-id pub-id-type="pmid">30840244</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J-M</given-names></name><name><surname>Choi</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>Y-H</given-names></name><name><surname>Jin</surname><given-names>SH</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Jang</surname><given-names>H-J</given-names></name><name><surname>Kim</surname><given-names>K-T</given-names></name><name><surname>Ryu</surname><given-names>SH</given-names></name><name><surname>Suh</surname><given-names>P-G</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>An activator of the camp/PKA/CREB pathway promotes osteogenesis from human mesenchymal stem cells</article-title><source>Journal of Cellular Physiology</source><volume>228</volume><fpage>617</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1002/jcp.24171</pub-id><pub-id pub-id-type="pmid">22886506</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Minami</surname><given-names>K</given-names></name><name><surname>Tamari</surname><given-names>K</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><name><surname>Pandya</surname><given-names>PH</given-names></name><name><surname>Saadatzadeh</surname><given-names>MR</given-names></name><name><surname>Kacena</surname><given-names>MA</given-names></name><name><surname>Pollok</surname><given-names>KE</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>Suppression of osteosarcoma progression by engineered lymphocyte-derived proteomes</article-title><source>Genes &amp; Diseases</source><volume>8</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1016/j.gendis.2022.08.007</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zha</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Sano</surname><given-names>T</given-names></name><name><surname>Aryal</surname><given-names>UK</given-names></name><name><surname>Sudo</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Counterintuitive production of tumor-suppressive secretomes from oct4- and c-myc-overexpressing tumor cells and mscs</article-title><source>Theranostics</source><volume>12</volume><fpage>3084</fpage><lpage>3103</lpage><pub-id pub-id-type="doi">10.7150/thno.70549</pub-id><pub-id pub-id-type="pmid">35547745</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>F-Y</given-names></name><name><surname>Dimmitt</surname><given-names>NH</given-names></name><name><surname>Moraes de Lima Perini</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>C-C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Injectable acylhydrazone-linked raft polymer hydrogels for sustained protein release and cell encapsulation</article-title><source>Advanced Healthcare Materials</source><volume>11</volume><elocation-id>e2101284</elocation-id><pub-id pub-id-type="doi">10.1002/adhm.202101284</pub-id><pub-id pub-id-type="pmid">34608768</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Zha</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Sano</surname><given-names>T</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Aryal</surname><given-names>UK</given-names></name><name><surname>Sudo</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Generation of the tumor-suppressive secretome from tumor cells</article-title><source>Theranostics</source><volume>11</volume><fpage>8517</fpage><lpage>8534</lpage><pub-id pub-id-type="doi">10.7150/thno.61006</pub-id><pub-id pub-id-type="pmid">34373756</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Zha</surname><given-names>R</given-names></name><name><surname>Jalali</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Sano</surname><given-names>T</given-names></name><name><surname>Vike</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Rispoli</surname><given-names>J</given-names></name><name><surname>Sudo</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Robling</surname><given-names>A</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>Overexpression of LRP5 enhanced the anti-breast cancer effects of osteocytes in bone</article-title><source>Bone Research</source><volume>9</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1038/s41413-021-00152-2</pub-id><pub-id pub-id-type="pmid">34230453</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsman</surname><given-names>G</given-names></name><name><surname>Zeerleder</surname><given-names>S</given-names></name><name><surname>Luken</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Extracellular histones, cell-free DNA, or nucleosomes: differences in immunostimulation</article-title><source>Cell Death &amp; Disease</source><volume>7</volume><elocation-id>e2518</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2016.410</pub-id><pub-id pub-id-type="pmid">27929534</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minami</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>A</given-names></name><name><surname>Wan</surname><given-names>Q</given-names></name><name><surname>Na</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Matsuura</surname><given-names>N</given-names></name><name><surname>Koizumi</surname><given-names>M</given-names></name><name><surname>Yin</surname><given-names>Y</given-names></name><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Nakshatri</surname><given-names>H</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Inhibitory effects of dopamine receptor D1 agonist on mammary tumor and bone metastasis</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>45686</elocation-id><pub-id pub-id-type="doi">10.1038/srep45686</pub-id><pub-id pub-id-type="pmid">28374823</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orchard</surname><given-names>S</given-names></name><name><surname>Ammari</surname><given-names>M</given-names></name><name><surname>Aranda</surname><given-names>B</given-names></name><name><surname>Breuza</surname><given-names>L</given-names></name><name><surname>Briganti</surname><given-names>L</given-names></name><name><surname>Broackes-Carter</surname><given-names>F</given-names></name><name><surname>Campbell</surname><given-names>NH</given-names></name><name><surname>Chavali</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>del-Toro</surname><given-names>N</given-names></name><name><surname>Duesbury</surname><given-names>M</given-names></name><name><surname>Dumousseau</surname><given-names>M</given-names></name><name><surname>Galeota</surname><given-names>E</given-names></name><name><surname>Hinz</surname><given-names>U</given-names></name><name><surname>Iannuccelli</surname><given-names>M</given-names></name><name><surname>Jagannathan</surname><given-names>S</given-names></name><name><surname>Jimenez</surname><given-names>R</given-names></name><name><surname>Khadake</surname><given-names>J</given-names></name><name><surname>Lagreid</surname><given-names>A</given-names></name><name><surname>Licata</surname><given-names>L</given-names></name><name><surname>Lovering</surname><given-names>RC</given-names></name><name><surname>Meldal</surname><given-names>B</given-names></name><name><surname>Melidoni</surname><given-names>AN</given-names></name><name><surname>Milagros</surname><given-names>M</given-names></name><name><surname>Peluso</surname><given-names>D</given-names></name><name><surname>Perfetto</surname><given-names>L</given-names></name><name><surname>Porras</surname><given-names>P</given-names></name><name><surname>Raghunath</surname><given-names>A</given-names></name><name><surname>Ricard-Blum</surname><given-names>S</given-names></name><name><surname>Roechert</surname><given-names>B</given-names></name><name><surname>Stutz</surname><given-names>A</given-names></name><name><surname>Tognolli</surname><given-names>M</given-names></name><name><surname>van Roey</surname><given-names>K</given-names></name><name><surname>Cesareni</surname><given-names>G</given-names></name><name><surname>Hermjakob</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The mintact project -- intact as a common curation platform for 11 molecular interaction databases</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D358</fpage><lpage>D363</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1115</pub-id><pub-id pub-id-type="pmid">24234451</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandya</surname><given-names>PH</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Saadatzadeh</surname><given-names>MR</given-names></name><name><surname>Bijangi-Vishehsaraei</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Sinn</surname><given-names>AL</given-names></name><name><surname>Trowbridge</surname><given-names>MA</given-names></name><name><surname>Coy</surname><given-names>KL</given-names></name><name><surname>Bailey</surname><given-names>BJ</given-names></name><name><surname>Young</surname><given-names>CN</given-names></name><name><surname>Ding</surname><given-names>J</given-names></name><name><surname>Dobrota</surname><given-names>EA</given-names></name><name><surname>Dyer</surname><given-names>S</given-names></name><name><surname>Elmi</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>Q</given-names></name><name><surname>Barghi</surname><given-names>F</given-names></name><name><surname>Shultz</surname><given-names>J</given-names></name><name><surname>Albright</surname><given-names>EA</given-names></name><name><surname>Shannon</surname><given-names>HE</given-names></name><name><surname>Murray</surname><given-names>ME</given-names></name><name><surname>Marshall</surname><given-names>MS</given-names></name><name><surname>Ferguson</surname><given-names>MJ</given-names></name><name><surname>Bertrand</surname><given-names>TE</given-names></name><name><surname>Wurtz</surname><given-names>LD</given-names></name><name><surname>Batra</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Renbarger</surname><given-names>JL</given-names></name><name><surname>Pollok</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Systems biology approach identifies prognostic signatures of poor overall survival and guides the prioritization of novel bet-chk1 combination therapy for osteosarcoma</article-title><source>Cancers</source><volume>12</volume><elocation-id>2426</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12092426</pub-id><pub-id pub-id-type="pmid">32859084</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sick</surname><given-names>E</given-names></name><name><surname>Jeanne</surname><given-names>A</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Dedieu</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Martiny</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cd47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest</article-title><source>British Journal of Pharmacology</source><volume>167</volume><fpage>1415</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2012.02099.x</pub-id><pub-id pub-id-type="pmid">22774848</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steiglitz</surname><given-names>BM</given-names></name><name><surname>Kreider</surname><given-names>JM</given-names></name><name><surname>Frankenburg</surname><given-names>EP</given-names></name><name><surname>Pappano</surname><given-names>WN</given-names></name><name><surname>Hoffman</surname><given-names>GG</given-names></name><name><surname>Meganck</surname><given-names>JA</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Höök</surname><given-names>M</given-names></name><name><surname>Birk</surname><given-names>DE</given-names></name><name><surname>Goldstein</surname><given-names>SA</given-names></name><name><surname>Greenspan</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Procollagen C proteinase enhancer 1 genes are important determinants of the mechanical properties and geometry of bone and the ultrastructure of connective tissues</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>238</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.1128/MCB.26.1.238-249.2006</pub-id><pub-id pub-id-type="pmid">16354695</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Zha</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hase</surname><given-names>M</given-names></name><name><surname>Aryal</surname><given-names>UK</given-names></name><name><surname>Lin</surname><given-names>C-C</given-names></name><name><surname>Li</surname><given-names>B-Y</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Preventing tumor progression to the bone by induced tumor-suppressing MscS</article-title><source>Theranostics</source><volume>11</volume><fpage>5143</fpage><lpage>5159</lpage><pub-id pub-id-type="doi">10.7150/thno.58779</pub-id><pub-id pub-id-type="pmid">33859739</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Aryal</surname><given-names>UK</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>PI3K-activated MSC proteomes inhibit mammary tumors via hsp90ab1 and MYH9</article-title><source>Molecular Therapy Oncolytics</source><volume>26</volume><fpage>360</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/j.omto.2022.08.003</pub-id><pub-id pub-id-type="pmid">36090473</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Hase</surname><given-names>M</given-names></name><name><surname>Zha</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>BY</given-names></name><name><surname>Yokota</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Suppression of breast cancer-associated bone loss with osteoblast proteomes via hsp90ab1/moesin-mediated inhibition of TGFβ/FN1/CD44 signaling</article-title><source>Theranostics</source><volume>12</volume><fpage>929</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.7150/thno.66148</pub-id><pub-id pub-id-type="pmid">34976221</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talbot</surname><given-names>J</given-names></name><name><surname>Dupuy</surname><given-names>M</given-names></name><name><surname>Morice</surname><given-names>S</given-names></name><name><surname>Rédini</surname><given-names>F</given-names></name><name><surname>Verrecchia</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antagonistic functions of connexin 43 during the development of primary or secondary bone tumors</article-title><source>Biomolecules</source><volume>10</volume><elocation-id>1240</elocation-id><pub-id pub-id-type="doi">10.3390/biom10091240</pub-id><pub-id pub-id-type="pmid">32859065</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taran</surname><given-names>SJ</given-names></name><name><surname>Taran</surname><given-names>R</given-names></name><name><surname>Malipatil</surname><given-names>NB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pediatric osteosarcoma: an updated review</article-title><source>Indian Journal of Medical and Paediatric Oncology</source><volume>38</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.4103/0971-5851.203513</pub-id><pub-id pub-id-type="pmid">28469335</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vailas</surname><given-names>M</given-names></name><name><surname>Syllaios</surname><given-names>A</given-names></name><name><surname>Hashemaki</surname><given-names>N</given-names></name><name><surname>Sotiropoulou</surname><given-names>M</given-names></name><name><surname>Schizas</surname><given-names>D</given-names></name><name><surname>Papalampros</surname><given-names>A</given-names></name><name><surname>Felekouras</surname><given-names>E</given-names></name><name><surname>Pikoulis</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Irreversible electroporation and sarcomas: where do we stand?</article-title><source>Journal of B.U.ON</source><volume>24</volume><fpage>1354</fpage><lpage>1359</lpage><pub-id pub-id-type="pmid">31646777</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldman</surname><given-names>AD</given-names></name><name><surname>Fritz</surname><given-names>JM</given-names></name><name><surname>Lenardo</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A guide to cancer immunotherapy: from T cell basic science to clinical practice</article-title><source>Nature Reviews. Immunology</source><volume>20</volume><fpage>651</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id><pub-id pub-id-type="pmid">32433532</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>DA</given-names></name><name><surname>Van Patten</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Multiple pathway signal transduction by the cAMP-dependent protein kinase</article-title><source>FASEB Journal</source><volume>8</volume><fpage>1227</fpage><lpage>1236</lpage><pub-id pub-id-type="doi">10.1096/fasebj.8.15.8001734</pub-id><pub-id pub-id-type="pmid">8001734</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Tremblay</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Schultz</surname><given-names>PG</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Identification of small-molecule inducers of pancreatic beta-cell expansion</article-title><source>PNAS</source><volume>106</volume><fpage>1427</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1073/pnas.0811848106</pub-id><pub-id pub-id-type="pmid">19164755</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Liao</surname><given-names>D</given-names></name><name><surname>Lv</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Kang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Up-Regulation of PCOLCE by Twist1 promotes metastasis in osteosarcoma</article-title><source>Theranostics</source><volume>9</volume><fpage>4342</fpage><lpage>4353</lpage><pub-id pub-id-type="doi">10.7150/thno.34090</pub-id><pub-id pub-id-type="pmid">31285765</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CC</given-names></name><name><surname>Beird</surname><given-names>HC</given-names></name><name><surname>Andrew Livingston</surname><given-names>J</given-names></name><name><surname>Advani</surname><given-names>S</given-names></name><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Reuben</surname><given-names>A</given-names></name><name><surname>Ingram</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>WL</given-names></name><name><surname>Ju</surname><given-names>Z</given-names></name><name><surname>Hong Leung</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Roszik</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Patel</surname><given-names>S</given-names></name><name><surname>Benjamin</surname><given-names>RS</given-names></name><name><surname>Somaiah</surname><given-names>N</given-names></name><name><surname>Conley</surname><given-names>AP</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Hwu</surname><given-names>P</given-names></name><name><surname>Gorlick</surname><given-names>R</given-names></name><name><surname>Lazar</surname><given-names>A</given-names></name><name><surname>Daw</surname><given-names>NC</given-names></name><name><surname>Lewis</surname><given-names>V</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Immuno-genomic landscape of osteosarcoma</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1008</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-14646-w</pub-id><pub-id pub-id-type="pmid">32081846</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pcolce is potent prognostic biomarker and associates with immune infiltration in gastric cancer</article-title><source>Frontiers in Molecular Biosciences</source><volume>7</volume><elocation-id>544895</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2020.544895</pub-id><pub-id pub-id-type="pmid">33392251</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J-F</given-names></name><name><surname>Pan</surname><given-names>X-H</given-names></name><name><surname>Zhang</surname><given-names>S-J</given-names></name><name><surname>Zhao</surname><given-names>C</given-names></name><name><surname>Qiu</surname><given-names>B-S</given-names></name><name><surname>Gu</surname><given-names>H-F</given-names></name><name><surname>Hong</surname><given-names>J-F</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Bi</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y-P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Cd47 blockade inhibits tumor progression human osteosarcoma in xenograft models</article-title><source>Oncotarget</source><volume>6</volume><fpage>23662</fpage><lpage>23670</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4282</pub-id><pub-id pub-id-type="pmid">26093091</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Mao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Lv</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: a meta-analysis and clinical observation</article-title><source>Medicine</source><volume>98</volume><elocation-id>e15582</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000015582</pub-id><pub-id pub-id-type="pmid">31083238</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Yi</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Analyzing the disease module associated with osteosarcoma via a network- and pathway-based approach</article-title><source>Experimental and Therapeutic Medicine</source><volume>16</volume><fpage>2584</fpage><lpage>2592</lpage><pub-id pub-id-type="doi">10.3892/etm.2018.6506</pub-id><pub-id pub-id-type="pmid">30210606</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>R</given-names></name><name><surname>Mao</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Ni</surname><given-names>C</given-names></name><name><surname>Zhong</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identification and preliminary validation of a four-gene signature to predict metastasis and survival in osteosarcoma</article-title><source>American Journal of Translational Research</source><volume>13</volume><fpage>12264</fpage><lpage>12284</lpage><pub-id pub-id-type="pmid">34956452</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Natino</surname><given-names>D</given-names></name><name><surname>Zhai</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MicroRNA‑22 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells</article-title><source>Molecular Medicine Reports</source><volume>17</volume><fpage>7209</fpage><lpage>7217</lpage><pub-id pub-id-type="doi">10.3892/mmr.2018.8790</pub-id><pub-id pub-id-type="pmid">29568877</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83768.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mohan</surname><given-names>Subburaman</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03z6z3n38</institution-id><institution>VA Loma Linda Healthcare System</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.10.18.512687" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.18.512687"/></front-stub><body><p>There are no known effective treatments available to date for the treatment of osteosarcomas, the earliest identified bone cancer that can spread to other tissues. In this study, the authors have used novel approaches to identify calreticulin and procollagen C-endopeptidase enhancer (PCOLCE) as osteosarcoma tumor suppressor proteins that inhibit osteosarcoma growth both in animal and in vitro cell culture models. These important findings may provide a basis for the future development of more efficient targeted therapies for the treatment of osteosarcomas.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83768.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Mohan</surname><given-names>Subburaman</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03z6z3n38</institution-id><institution>VA Loma Linda Healthcare System</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Zhao</surname><given-names>Haibo</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0431mgz06</institution-id><institution>Southern California Institute for Research and Education</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.10.18.512687">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.10.18.512687v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Mone Zaidi as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Haibo Zhao (Reviewer #1).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) The increases in both trabecular and cortical bone mass in PKA-induced MSC conditional medium (Figure 3) and recombinant calreticulin (Figure 5A-5C) treated mice may be in part due to enhanced osteoblast differentiation from MSC and/or increased bone matrix deposition in addition to decreased bone destruction resulted from attenuation of osteosarcoma tumor growth and invasion in bone. Have the authors examined the effects of PKA-induced MSC conditional medium and calreticulin on osteoblast differentiation and bone matrix deposition?</p><p>2) Although the authors have shown that PKA-induced MSC conditional medium (suppl Figure 2) and recombinant calreticulin (Figure 5A) decreased tumor volume in bone, no evidence has been provided that the two treatments inhibit tumor cell proliferation and survival in vivo by immunohistochemistry detection of Ki-67 and cleaved-caspase 3.</p><p>3) The results presented for the Calreticulin-CD47 signaling axis dissected in Figure 5 appear incomplete. The metadata in panel F suggests high expression of Calr coupled with low expression of CD47 improves survival for patients with all types of cancer. The only data the authors present to evaluate whether the levels of CD47 affect its interaction with Calreticulin are shown on panel E, but in U2OS cells, low levels of CD47 prevent Calreticulin's tumor suppressor function. Since this suggests that the Calr-CD47 interaction differs between osteosarcoma cells and &quot;all cancer&quot; it would help if this were mentioned more explicitly in the manuscript. More importantly, this argument can be strengthened with the addition of further evidence, such as an MTT assay that tests the effect of the presence of both Calr and CD47 on Osteosarcoma viability, as done for PCOLCE and APP in Figure 7 panel E.</p><p>4) Is there any data demonstrating that the siRNA knockdown of CD47 and PCOLCE in Figure 5E and Figure 7F was effective? Although the western blot data in those panels is convincing, it is difficult to accept without evidence that the intended protein levels were reduced by siRNA.</p><p>5) Some graphs indicate statistically significant differences, but the difference in means looks minimal. Examples include Figure 1E, Figure 3A BMD, Figure 3B, Figure 3C, Figure 3D, Figure 5B, and 5C. A possible solution would be to include source data for the graphs, and/or to adjust the plotted graphs to include individual points measured.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1) The increases in both trabecular and cortical bone mass in PKA-induced MSC conditional medium (Figure 3) and recombinant calreticulin (Figure 5A-5C) treated mice may be in part due to enhanced osteoblast differentiation from MSC and/or increased bone matrix deposition in addition to decreased bone destruction resulted from attenuation of osteosarcoma tumor growth and invasion in bone. Have the authors examined the effects of PKA-induced MSC conditional medium and calreticulin on osteoblast differentiation and bone matrix deposition?</p><p>2) Although the authors have shown that PKA-induced MSC conditional medium (suppl Figure 2) and recombinant calreticulin (Figure 5A) decreased tumor volume in bone, no evidence has been provided that the two treatments inhibit tumor cell proliferation and survival in vivo by immunohistochemistry detection of Ki-67 and cleaved-caspase 3.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>In this manuscript, Li et al. expand their recently published work wherein they interrogate the proteomes of mesenchymal stem cell (MSC) culture media following stimulation with signaling pathways that exacerbate cancerous states, such as WNT and PI3K, to identify tumor suppressor proteins. They found that activation of MSCs with PKA also results in conditioned media capable of reducing the viability and motility of osteosarcoma cell lines in vitro. Moreover, this conditioned media was synergistic with anti-cancer drugs, effectively reduced the size of osteosarcoma tumors implanted in the bones of mice, and restored the bone loss caused by these tumors. By comparing transcripts and proteins identified within PKA-induced MSC conditioned media with public cancer databases, they investigated whether several proteins high in osteosarcoma in humans might paradoxically function as tumor suppressors. They focused on CALRETICULIN-CD47, PCOLCE-APP, and CALRETICULIN-APP interactions to highlight their approach as a proof of concept that perhaps identifying the proteins secreted by cancer cells can offer novel approaches to target osteosarcomas. Although they present substantial work, the following issues might be worth addressing.</p><p>– The results presented for the Calreticulin-CD47 signaling axis dissected in Figure 5 appear incomplete. The metadata in panel F suggests high expression of Calr coupled with low expression of CD47 improves survival for patients with all types of cancer. The only data the authors present to evaluate whether the levels of CD47 affect its interaction with Calreticulin are shown on panel E, but in U2OS cells, low levels of CD47 prevent Calreticulin's tumor suppressor function. Since this suggests that the Calr-CD47 interaction differs between osteosarcoma cells and &quot;all cancer&quot; it would help if this were mentioned more explicitly in the manuscript. More importantly, this argument can be strengthened with the addition of further evidence, such as an MTT assay that tests the effect of the presence of both Calr and CD47 on Osteosarcoma viability, as done for PCOLCE and APP in Figure 7 panel E.</p><p>– Is there any data demonstrating that siRNA knockdown of CD47 and PCOLCE in Figure 5E and Figure 7F was effective? Although the western blot data in those panels is convincing, it is difficult to accept without evidence that the intended protein levels were reduced by siRNA.</p><p>– There are enough differences between CW-CM combined with the different chemotherapeutic agents that should probably be described better in the Results section. The authors mention that &quot;Importantly, the simultaneous application of CW-MSC CM significantly lowered the effective concentrations of MTX, DOX, and CIS in both TT2 and U2OS cells.&quot; Also, what is the sample size for the data plotted? At what doses were statistically significant differences observed?</p><p>– Some graphs indicate statistically significant differences, but the difference in means look minimal. Examples include Figure 1E, Figure 3A BMD, Figure 3B, Figure 3C, Figure 3D, Figure 5B, and 5C. A possible solution would be to include source data for the graphs, and/or to adjust the plotted graphs to include individual points measured.</p><p>– Some of the writing can use further proofreading.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83768.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) The increases in both trabecular and cortical bone mass in PKA-induced MSC conditional medium (Figure 3) and recombinant calreticulin (Figure 5A-5C) treated mice may be in part due to enhanced osteoblast differentiation from MSC and/or increased bone matrix deposition in addition to decreased bone destruction resulted from attenuation of osteosarcoma tumor growth and invasion in bone. Have the authors examined the effects of PKA-induced MSC conditional medium and calreticulin on osteoblast differentiation and bone matrix deposition?</p></disp-quote><p>Thank you for the comment on osteoblast differentiation. In the revised manuscript, we tested the effects of PKA-induced MSC conditioned medium (CM) and calreticulin on the differentiation and mineralization of osteoblasts using MC3T3 osteoblast cells. The differentiation was evaluated by examining the expression levels of type I collagen, alkaline phosphatase, and osteocalcin by Western blotting. The matrix deposition was evaluated by Arizalin red staining in an osteogenic medium. We included the results in Figure 5—figure supplement 2 in the revision.</p><disp-quote content-type="editor-comment"><p>2) Although the authors have shown that PKA-induced MSC conditional medium (suppl Figure 2) and recombinant calreticulin (Figure 5A) decreased tumor volume in bone, no evidence has been provided that the two treatments inhibit tumor cell proliferation and survival in vivo by immunohistochemistry detection of Ki-67 and cleaved-caspase 3.</p></disp-quote><p>Thank you for the comment on the effect of PKA-induced MSC-conditioned medium and calreticulin on the expression of Ki-67 and cleaved Caspase 3 in tumor-invaded bone sections. As suggested, we conducted immunohistochemistry and detected these two proteins in the section of the proximal tibia. We included the results in Figure 3—figure supplement 3 and Figure 5—figure supplement 1 in the revision.</p><disp-quote content-type="editor-comment"><p>3) The results presented for the Calreticulin-CD47 signaling axis dissected in Figure 5 appear incomplete. The metadata in panel F suggests high expression of Calr coupled with low expression of CD47 improves survival for patients with all types of cancer. The only data the authors present to evaluate whether the levels of CD47 affect its interaction with Calreticulin are shown on panel E, but in U2OS cells, low levels of CD47 prevent Calreticulin's tumor suppressor function. Since this suggests that the Calr-CD47 interaction differs between osteosarcoma cells and &quot;all cancer&quot; it would help if this were mentioned more explicitly in the manuscript. More importantly, this argument can be strengthened with the addition of further evidence, such as an MTT assay that tests the effect of the presence of both Calr and CD47 on Osteosarcoma viability, as done for PCOLCE and APP in Figure 7 panel E.</p></disp-quote><p>As suggested, we evaluated the CALR-CD47 interactions using the same approach to evaluate the PCOLCE-APP interactions in Figure 7E. Silencing CD47 also downregulated MTT-based viability, whereas it significantly suppressed Calr-induced tumor inhibition in U2OS OS cells, TT2 OS cells, MDA-MB-231 breast cancer cells, and PANC1 pancreatic cells. We included the results in Figure 5—figure supplement 4 in the revision.</p><disp-quote content-type="editor-comment"><p>4) Is there any data demonstrating that the siRNA knockdown of CD47 and PCOLCE in Figure 5E and Figure 7F was effective? Although the western blot data in those panels is convincing, it is difficult to accept without evidence that the intended protein levels were reduced by siRNA.</p></disp-quote><p>We apologize for not showing the silencing effect by siRNA for CD47 in Figure 5E. We included the results in Figure 5—figure supplement 3 in the revision.</p><disp-quote content-type="editor-comment"><p>5) Some graphs indicate statistically significant differences, but the difference in means looks minimal. Examples include Figure 1E, Figure 3A BMD, Figure 3B, Figure 3C, Figure 3D, Figure 5B, and 5C. A possible solution would be to include source data for the graphs, and/or to adjust the plotted graphs to include individual points measured.</p></disp-quote><p>We appreciate the comment and suggestion. We included source data for the graphs in addition to the description of the mean and standard deviation. Particularly, individual data points were included in most of the plots.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1) The increases in both trabecular and cortical bone mass in PKA-induced MSC conditional medium (Figure 3) and recombinant calreticulin (Figure 5A-5C) treated mice may be in part due to enhanced osteoblast differentiation from MSC and/or increased bone matrix deposition in addition to decreased bone destruction resulted from attenuation of osteosarcoma tumor growth and invasion in bone. Have the authors examined the effects of PKA-induced MSC conditional medium and calreticulin on osteoblast differentiation and bone matrix deposition?</p></disp-quote><p>Done</p><disp-quote content-type="editor-comment"><p>2) Although the authors have shown that PKA-induced MSC conditional medium (suppl Figure 2) and recombinant calreticulin (Figure 5A) decreased tumor volume in bone, no evidence has been provided that the two treatments inhibit tumor cell proliferation and survival in vivo by immunohistochemistry detection of Ki-67 and cleaved-caspase 3.</p></disp-quote><p>Done</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>In this manuscript, Li et al. expand their recently published work wherein they interrogate the proteomes of mesenchymal stem cell (MSC) culture media following stimulation with signaling pathways that exacerbate cancerous states, such as WNT and PI3K, to identify tumor suppressor proteins. They found that activation of MSCs with PKA also results in conditioned media capable of reducing the viability and motility of osteosarcoma cell lines in vitro. Moreover, this conditioned media was synergistic with anti-cancer drugs, effectively reduced the size of osteosarcoma tumors implanted in the bones of mice, and restored the bone loss caused by these tumors. By comparing transcripts and proteins identified within PKA-induced MSC conditioned media with public cancer databases, they investigated whether several proteins high in osteosarcoma in humans might paradoxically function as tumor suppressors. They focused on CALRETICULIN-CD47, PCOLCE-APP, and CALRETICULIN-APP interactions to highlight their approach as a proof of concept that perhaps identifying the proteins secreted by cancer cells can offer novel approaches to target osteosarcomas. Although they present substantial work, the following issues might be worth addressing.</p><p>– The results presented for the Calreticulin-CD47 signaling axis dissected in Figure 5 appear incomplete. The metadata in panel F suggests high expression of Calr coupled with low expression of CD47 improves survival for patients with all types of cancer. The only data the authors present to evaluate whether the levels of CD47 affect its interaction with Calreticulin are shown on panel E, but in U2OS cells, low levels of CD47 prevent Calreticulin's tumor suppressor function. Since this suggests that the Calr-CD47 interaction differs between osteosarcoma cells and &quot;all cancer&quot; it would help if this were mentioned more explicitly in the manuscript. More importantly, this argument can be strengthened with the addition of further evidence, such as an MTT assay that tests the effect of the presence of both Calr and CD47 on Osteosarcoma viability, as done for PCOLCE and APP in Figure 7 panel E.</p></disp-quote><p>Done</p><disp-quote content-type="editor-comment"><p>– Is there any data demonstrating that siRNA knockdown of CD47 and PCOLCE in Figure 5E and Figure 7F was effective? Although the western blot data in those panels is convincing, it is difficult to accept without evidence that the intended protein levels were reduced by siRNA.</p></disp-quote><p>Done</p><disp-quote content-type="editor-comment"><p>– There are enough differences between CW-CM combined with the different chemotherapeutic agents that should probably be described better in the Results section. The authors mention that &quot;Importantly, the simultaneous application of CW-MSC CM significantly lowered the effective concentrations of MTX, DOX, and CIS in both TT2 and U2OS cells.&quot; Also, what is the sample size for the data plotted? At what doses were statistically significant differences observed?</p></disp-quote><p>Thank you for the comment. We included source data for the graphs in addition to the description of the mean and standard deviation. Particularly, individual data points were included in most of the plots.</p><disp-quote content-type="editor-comment"><p>– Some graphs indicate statistically significant differences, but the difference in means look minimal. Examples include Figure 1E, Figure 3A BMD, Figure 3B, Figure 3C, Figure 3D, Figure 5B, and 5C. A possible solution would be to include source data for the graphs, and/or to adjust the plotted graphs to include individual points measured.</p></disp-quote><p>Done</p><disp-quote content-type="editor-comment"><p>– Some of the writing can use further proofreading.</p></disp-quote><p>Thank you for the comment.</p></body></sub-article></article>